Afecta Pharmaceuticals to Present at the 2016 American Chemical Society Meeting in San Diego

Share Article

Friday, March 11, 2016, Irvine, CA: Afecta Pharmaceuticals, a privately-held, clinical-stage biopharmaceutical company developing novel treatments for women and children, will present at the 2016 American Chemical Society meeting on March 15, 2016, at the San Diego Convention Center.

George Nicola, PhD, MBA, Senior Vice President of Computational Pharmacology at Afecta Pharmaceuticals, will present “Computers in Chemistry” at the American Chemical Society meeting. Dr. Nicola will present both an oral and poster presentation on the topic of “big data” challenges in drug development programs.

About Afecta Pharmaceuticals, Inc.

Afecta Pharmaceuticals, based in Irvine, California, is developing novel drugs for Women’s and Children’s health by leveraging its proprietary drug design platform, Pharmetrx™, which enables prediction of new indications for known drug targets, mechanisms of action based on existing molecules, new molecular entities, as well as likely side effect profiles and potential toxicological issues. Pharmetrx™ can also be applied to the design of new molecules for known targets and orphan targets using advanced QSAR models for collaborative research and development programs with industry partners in any disease area.

Pharmetrx™ is built from proprietary, open source, and commercial software that has been integrated into a streamlined workflow that results in a “Pharmacological Fingerprint” of any drug-like compound and can incorporate new QSAR data into predictive models by the Afecta computational pharmacology team. Pharmetrx™ has also proven to be useful when there is a need to re-design an existing molecule for a known or emerging drug target that can be accelerated into clinical development, especially when gene-based disease sub-types can be identified in patient populations.

Afecta has successfully applied its systems biology and computational approaches to discover new applications of existing molecules for use in impulsive aggression in children with disorders such as ADHD and Autism that have been licensed to Supernus Pharmaceuticals. The first “de-risked” lead drug licensed to Supernus, SPN810, is in Phase III clinical trials and has received FDA Fast Track designation. Afecta currently has several active discovery and development programs in other disease areas related to Women’s and Children’s health as well.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kamron Shahbahrami
Visit website